Tyra Biosciences (NASDAQ:TYRA) Trading Down 7.3%

Tyra Biosciences, Inc. (NASDAQ:TYRA)’s stock price was down 7.3% on Thursday . The company traded as low as $14.79 and last traded at $14.84. Approximately 34,082 shares were traded during mid-day trading, a decline of 74% from the average daily volume of 129,525 shares. The stock had previously closed at $16.00.

Analyst Upgrades and Downgrades

Several analysts have weighed in on TYRA shares. HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective (up previously from $19.00) on shares of Tyra Biosciences in a research report on Wednesday, March 20th. Wedbush restated an “outperform” rating and set a $28.00 target price on shares of Tyra Biosciences in a report on Thursday, March 21st.

Tyra Biosciences Trading Up 3.7 %

The firm has a fifty day moving average of $17.38 and a 200 day moving average of $14.85. The company has a market capitalization of $822.99 million, a P/E ratio of -9.73 and a beta of 1.12.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Tuesday, March 19th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.05). Sell-side analysts anticipate that Tyra Biosciences, Inc. will post -1.89 EPS for the current fiscal year.

Insider Activity

In other news, COO Daniel Bensen sold 1,501 shares of Tyra Biosciences stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $20.00, for a total transaction of $30,020.00. Following the transaction, the chief operating officer now directly owns 451,480 shares of the company’s stock, valued at approximately $9,029,600. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 15,816 shares of company stock valued at $298,165 in the last ninety days. Corporate insiders own 18.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TYRA. Kynam Capital Management LP purchased a new position in Tyra Biosciences in the 4th quarter worth approximately $4,712,000. Victory Capital Management Inc. increased its stake in Tyra Biosciences by 53.4% in the 4th quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock worth $696,000 after acquiring an additional 17,490 shares during the last quarter. Fishman Jay A Ltd. MI bought a new stake in Tyra Biosciences in the 1st quarter worth approximately $246,000. Wellington Management Group LLP increased its stake in Tyra Biosciences by 18.5% in the 3rd quarter. Wellington Management Group LLP now owns 94,112 shares of the company’s stock worth $1,296,000 after acquiring an additional 14,676 shares during the last quarter. Finally, Corton Capital Inc. bought a new stake in Tyra Biosciences in the 3rd quarter worth approximately $152,000. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.